vs
Side-by-side financial comparison of Bone Biologics Corp (BBLG) and ORAMED PHARMACEUTICALS INC. (ORMP). Click either name above to swap in a different company.
Bone Biologics Corp is a clinical-stage biotechnology firm focused on developing orthobiologic products to boost bone regeneration and healing for orthopedic surgery patients, including spinal fusion recipients. It mainly operates in the U.S. healthcare market, targeting orthopedic care and regenerative medicine segments.
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
BBLG vs ORMP — Head-to-Head
Income Statement — Q1 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $255 | $0 |
| Net Profit | $-866.0K | $10.0M |
| Gross Margin | — | — |
| Operating Margin | -354327.8% | — |
| Net Margin | -339596.1% | — |
| Revenue YoY | -54.1% | — |
| Net Profit YoY | 76.7% | 198.2% |
| EPS (diluted) | $-1.31 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $2.0M | ||
| Q1 24 | $255 | — | ||
| Q4 23 | $348 | $0 | ||
| Q3 23 | $536 | $0 | ||
| Q2 23 | $428 | $674.0K |
| Q4 25 | — | $10.0M | ||
| Q3 25 | — | $48.4M | ||
| Q2 25 | — | $13.3M | ||
| Q1 25 | — | $-7.6M | ||
| Q1 24 | $-866.0K | — | ||
| Q4 23 | $-1.5M | $12.9M | ||
| Q3 23 | $-1.9M | $-3.2M | ||
| Q2 23 | $-1.8M | $-1.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.7% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -225.0% | ||
| Q1 24 | -354327.8% | — | ||
| Q4 23 | -333335.6% | — | ||
| Q3 23 | -388225.7% | — | ||
| Q2 23 | -710249.5% | -562.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -382.1% | ||
| Q1 24 | -339596.1% | — | ||
| Q4 23 | -445369.3% | — | ||
| Q3 23 | -358154.7% | — | ||
| Q2 23 | -413373.4% | -177.2% |
| Q4 25 | — | $0.25 | ||
| Q3 25 | — | $1.13 | ||
| Q2 25 | — | $0.31 | ||
| Q1 25 | — | $-0.19 | ||
| Q1 24 | $-1.31 | — | ||
| Q4 23 | $31.30 | $0.33 | ||
| Q3 23 | $-4.90 | $-0.08 | ||
| Q2 23 | $-5.21 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $51.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.7M | $199.7M |
| Total Assets | $3.8M | $230.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $51.4M | ||
| Q3 25 | — | $57.1M | ||
| Q2 25 | — | $17.6M | ||
| Q1 25 | — | $3.7M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $66.8M | ||
| Q3 23 | — | $49.4K | ||
| Q2 23 | — | $943.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $74.5M | ||
| Q2 23 | — | — |
| Q4 25 | — | $199.7M | ||
| Q3 25 | — | $203.3M | ||
| Q2 25 | — | $154.5M | ||
| Q1 25 | — | $140.8M | ||
| Q1 24 | $3.7M | — | ||
| Q4 23 | $2.9M | $163.8M | ||
| Q3 23 | $3.8M | $149.1M | ||
| Q2 23 | $5.7M | $151.5M |
| Q4 25 | — | $230.9M | ||
| Q3 25 | — | $220.5M | ||
| Q2 25 | — | $161.7M | ||
| Q1 25 | — | $147.5M | ||
| Q1 24 | $3.8M | — | ||
| Q4 23 | $3.7M | $220.6M | ||
| Q3 23 | $5.0M | $230.9M | ||
| Q2 23 | $7.6M | $156.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 0.50× | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $-466.0K |
| Free Cash FlowOCF − Capex | — | $-468.0K |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-466.0K | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-3.5M | ||
| Q1 25 | — | $-3.5M | ||
| Q1 24 | $-1.3M | — | ||
| Q4 23 | $-2.0M | $-1.4M | ||
| Q3 23 | $-2.6M | $-694.0K | ||
| Q2 23 | $-3.6M | $-2.6M |
| Q4 25 | — | $-468.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-3.5M | ||
| Q1 25 | — | $-3.5M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $-1.4M | ||
| Q3 23 | — | $-726.0K | ||
| Q2 23 | — | $-2.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -176.1% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -393.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 3.0% |
| Q4 25 | — | -0.05× | ||
| Q3 25 | — | -0.03× | ||
| Q2 25 | — | -0.27× | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -0.11× | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
